These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 2585889)

  • 1. Probucol-induced QT prolongation and torsades de pointes.
    Matsuhashi H; Onodera S; Kawamura Y; Hasebe N; Kohmura C; Yamashita H; Tobise K
    Jpn J Med; 1989; 28(5):612-5. PubMed ID: 2585889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of probucol on QT/QS2 relation and systolic time intervals.
    Romics L; Littmann L; László Z; Fenyvesi T
    Int J Cardiol; 1988 Jun; 19(3):303-8. PubMed ID: 3397194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Probucol-induced QT prolongation and syncope.
    Tamura M; Ueki Y; Ohtsuka E; Oribe M; Seita M; Oribe K; Ito M
    Jpn Circ J; 1994 May; 58(5):374-7. PubMed ID: 8022053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Ventricular tachyarrhythmia induced by low doses of sotalol: torsade de pointes or polymorphous ventricular tachycardia?].
    Ophoff N; Toker Y
    Z Kardiol; 1988 Jun; 77(6):393-7. PubMed ID: 3213144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolongation of the QT interval induced by probucol: demonstration of a method for determining QT interval change induced by a drug.
    Browne KF; Prystowsky EN; Heger JJ; Cerimele BJ; Fineberg N; Zipes DP
    Am Heart J; 1984 Apr; 107(4):680-4. PubMed ID: 6702562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Propranolol for probucol-induced QT prolongation with polymorphic ventricular tachycardia.
    Kajinami K; Takekoshi N; Mabuchi H
    Lancet; 1993 Jan; 341(8837):124-5. PubMed ID: 8093399
    [No Abstract]   [Full Text] [Related]  

  • 7. Assessment of drug-induced proarrhythmia: The importance of study design in the rabbit left ventricular wedge model.
    Lu HR; Gallacher DJ; Yan GX
    J Pharmacol Toxicol Methods; 2016; 81():151-60. PubMed ID: 27374776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noninvasive cardiac activation imaging of ventricular arrhythmias during drug-induced QT prolongation in the rabbit heart.
    Han C; Pogwizd SM; Killingsworth CR; Zhou Z; He B
    Heart Rhythm; 2013 Oct; 10(10):1509-15. PubMed ID: 23773986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
    Lu HR; Yan GX; Gallacher DJ
    J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Probucol aggravates long QT syndrome associated with a novel missense mutation M124T in the N-terminus of HERG.
    Hayashi K; Shimizu M; Ino H; Yamaguchi M; Terai H; Hoshi N; Higashida H; Terashima N; Uno Y; Kanaya H; Mabuchi H
    Clin Sci (Lond); 2004 Aug; 107(2):175-82. PubMed ID: 15043509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. QT prolongation and torsade de pointes ventricular tachycardia produced by Ketanserin.
    Aldariz AE; Romero H; Baroni M; Baglivo H; Esper RJ
    Pacing Clin Electrophysiol; 1986 Nov; 9(6):836-41. PubMed ID: 2432486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of probucol, a typical hERG expression inhibitor, on in vivo QT interval prolongation in conscious dogs.
    Nogawa H; Kawai T; Yajima M; Miura M; Ogawa T; Murakami K
    Eur J Pharmacol; 2013 Nov; 720(1-3):29-37. PubMed ID: 24211675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypocalcemic Torsades de Pointes.
    Akiyama T; Batchelder J; Worsman J; Moses HW; Jedlinski M
    J Electrocardiol; 1989 Jan; 22(1):89-92. PubMed ID: 2921582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. QT interval measurement in ventricular pacing: Implications for assessment of drug effects and pro-arrhythmia risk.
    Schurr JW; Grewal PK; Fan R; Rashba E
    J Electrocardiol; 2022; 70():13-18. PubMed ID: 34826635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquired prolongation of QT interval as a risk factor for torsade de pointes ventricular tachycardia: a narrative review for the anesthesiologist and intensivist.
    Uvelin A; Pejaković J; Mijatović V
    J Anesth; 2017 Jun; 31(3):413-423. PubMed ID: 28229241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care.
    Roden DM; Woosley RL; Primm RK
    Am Heart J; 1986 Jun; 111(6):1088-93. PubMed ID: 3716982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation.
    Eckardt L; Breithardt G; Haverkamp W
    J Pharmacol Exp Ther; 2002 Jan; 300(1):64-71. PubMed ID: 11752098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. QT prolongation and possibility of ventricular arrhythmias after intracoronary papaverine.
    Inoue T; Asahi S; Takayanagi K; Morooka S; Takabatake Y
    Cardiology; 1994; 84(1):9-13. PubMed ID: 7511988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. QT and TdP. QT: an unreliable predictor of proarrhythmia.
    Hondeghem LM
    Acta Cardiol; 2008 Feb; 63(1):1-7. PubMed ID: 18372573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new preclinical biomarker for risk of Torsades de Pointes: drug-induced reduction of the cardiac electromechanical window.
    Vargas HM
    Br J Pharmacol; 2010 Dec; 161(7):1441-3. PubMed ID: 20698854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.